The Royal Pharmaceutical Society (RPS) Wales and the Association of the British Pharmaceutical Industry (ABPI) co-hosted a drop-in session to inform members
of the Senedd (MSs) about the action taken by pharmacists to make medicines use more sustainable.
At a 'drop-in' session the ABPI, RPS members and staff had the opportunity to speak to a number of MSs from all political parties.
"With medicines accounting for around 25 per cent of the NHS carbon emissions, conversations were based around the key recommendations to reverse this from the RPS'
policies on sustainability," said RPS.
The three key themes emphasised in all discussions were- the need to educate the public and change behaviours to avoid stockpiling medicines; How the clinical skills
of prescribing pharmacists can be used for appropriate de-prescribing and switching patients to low carbon options; and importance of tackling waste.
RPS Wales Director Elen Jones said: "It was fantastic to see how interested and engaged the politicians were around these important issues. By the end of our
conversations, they all clearly understood and supported the importance of pharmacy leadership in this area, as well as the need for the link between climate
change and medicines to be better understood by patients.
The GP Community Pharmacist Consultation Service (GP CPCS) is also delivering 'unexpected' insights to help transform patient care and facilitate integrated
working between pharmacists and GPs across Greater Manchester.
Since April 2021, almost 14,000 appointments have been referred using the GP CPCS across the Greater Manchester Health and Social Care Partnership - a figure that
is growing as its success gathers pace and they continue to support practices to increase referral activity.
Joshua Nolan, a pharmacist at Internet Pharmacy in Heywood, one of the first in the area to join the referral service, said: "The number of patients we're seeing
from GP CPCS has been building consistently month-on-month. On average we see around 50 patients, but recently we recorded 53 in just one week."
The pharmacist, who has been practising for six years and is also an independent prescriber, believes the GP CPCS has helped bring about more awareness to the
clinical services community pharmacy can offer.
The Pharmaceutical Services Negotiating Committee (PSNC) has reminded Community pharmacy contractors to ensure that the correct flu vaccines are being used for
each patient cohort.
The pharmacies have also been asked to ensure that they recorded accurately in the patient's clinical record for the NHS Flu Vaccination Service.
The move was followed by PSNC after the cases where the standard egg-cultured quadrivalent influenza vaccine (QIVe) was administered in the 65 years and over patient
cohort.
PSNC said: "On investigation, it appears that a number of these errors are due to data input errors; however, it is important to be careful when selecting a flu
vaccine for this patient cohort as there is no provision for the use of the QIVe vaccine in patients aged 65 years and over in the NHS Flu Vaccination Service."
The Joint Committee on Vaccination and Immunisation has advised it is not an effective intervention for patients aged 65 years and over.
The Pharmaceutical Services Negotiating Committee (PSNC) has launched a four point plan at its parliamentary drop-in event for MPs and peers hosted on Tuesday
(15 November).
The event lasted for two hours, during which MPs had the opportunity to drop-in and have their blood pressure measured by pharmacists with experience of working on
the front-line and were briefed on the urgent need for action to address the pressures on the sector.
Outline of the four-point plan:
Resolve the funding squeeze: Community pharmacy needs an immediate funding uplift to prevent large-scale pharmacy closures, as well as emergency business relief to
get through this winter.
Tackle regulatory and other burdens: Pharmacies must be protected from medicines market shocks, supported to help them weather the workforce crisis, helped to free
up capacity and freed from red tape that does not enhance patient care.
Help pharmacies to expand their role in primary care: Pharmacies could do more to support the delivery of primary care for example through offering clinical services
for long-term conditions - like hypertension, diabetes and respiratory disease, supporting people to adopt healthier lifestyles and prevent the development of
long-term conditions, medicines optimisation, and a much wider variety of NHS vaccinations.
The Pharmacists' Defence Association (PDA) has raised concerns over "certain elements" of the Pharmaceutical Society of Northern Ireland (PSNI)'s consultation
on pharmacy staffing levels.
PSNI recently consulted on its draft guidance for pharmacy staffing levels which sets out to explain what pharmacy owners and superintendents must do to ensure that
each pharmacy has enough skilled and qualified staff. This includes having an appropriate skill mix, to provide safe and effective pharmacy services which comply
with the standards.
PDA said that the role of the 'responsible pharmacist' has not been "fully acknowledged" and that more clarification is needed.
The association has made a few recommendations to PSNI that includes: the guidance must explicitly recognise the statutory role of the responsible pharmacist and
their authority in securing the safe operations within the pharmacy.
"The guidance should specify that pharmacy owners and superintendents must ensure that they do not set incentives or targets which may compromise the professional
judgement of staff."
It also recommended that unregistered staff (including unregistered managers) are accountable firstly to the responsible pharmacist for any activity involving the
clinical care of patients (for example unregistered managers must not interfere in diary bookings for vaccinations).
The Health Education England (HEE) has allocated £440,000 to help upskill pharmacists working in adult critical care across England.
UK Clinical Pharmacy Association (UKCPA) has confirmed with HEE that UKCPA critical care courses meet the criteria for this funding, for courses that complete before
31 March 2023.
"The funding is expected to exceed demand and so it is likely that bids for these UKCPA courses will be approved by HEE, as they meet the learning outcomes in the
new RPS/UKCPA/FICM specialist critical care curricula (in development)," said UKCPA.
David Webb, the Chief Pharmaceutical Officer for England, acknowledged that the "pressure in the system is high", but urged everyone to "keep our eye on the
design" of the NHS plan, adding that the "the objective is to bring the different parts of primary care together" in the patient interest.
Speaking during the opening keynote session at the the National Pharmacy Association (NPA) conference held on Thursday (13 October), he added that the NHS plan
intends to bring different parts of primary care together to help patients.
He said the new integrated care boards (ICBs) are a key strategic framework as they provide the "potential to form partnerships to deliver integrated services across
larger populations".
"ICBs will want to work with Local Pharmaceutical Committees to plan for the local population and the new community pharmacy clinical leads in ICBs, who have been
funded by NHS England, are there to advise."
He explained that once an ICB takes over the commissioning of pharmaceutical services (which they are all due to do by April 2023), it could use its funds to
commission a local enhanced service as an add on to an advanced service. For instance, a CVD risk assessment could be added to the blood pressure check service.
There is no doubt that the pandemic has changed the way healthcare professionals work within the primary care setting. The advent of Covid-19 meant that we all
had to rapidly modify the way we supported and met the needs of patients, some of whom saw the services they usually took for granted, virtually cease overnight.
There are around 15 million people in England living with long-term health conditions including asthma. These people have the greatest healthcare needs of the whole
population with 50 per cent of all GP appointments and 70 per cent of all bed days taken by this cohort of patients, and their treatment and care absorbing 70 per
cent of acute and primary care budgets in England.
This situation isn't going to improve any time soon. In the past, most people had a single condition, today multi-morbidity is becoming the norm. At the start of the
pandemic, the Royal College of General Practice and British Medical Association issued guidance to practices on prioritising workload. This included the importance
of maintaining long-term condition reviews in asthma, COPD and diabetes, along with appropriate transition of at-risk warfarin patients. These reviews were deemed as
essential workstreams for patients considered to be at high risk.
Traditionally, the unique skills set of a pharmacist has meant that we have played a major role in supporting these patients. I work with a team of over 90 clinical
pharmacists who, in partnership with individual practices, PCNs, CCGs and STPs, help with the long-term management of people with chronic conditions. But the onset
of Covid-19 meant that we now had to plug a potential gap in service provision, and quickly.
Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed
with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year.
It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S.
government's Medicare plan for people age 65 and over, potential side effects and cost.
One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000
per year.
"Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a
massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer.
Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced
the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain
swelling and brain bleeding.
Talk of hub and spoke models has been rumbling on for as long as I can remember. The topic has once again hit the headlines as the government announced a
fresh consultation for its proposed changes, calling on all interested parties to submit their views by 8th June.
The argument for hub and spoke is to allow independents to have the same level playing field as the larger groups who have been operating this model for some time.
The government also sees significant efficiency gains in centralisation, arguing this will free pharmacists time away from dispensing to focus on clinical services.
The latest consultation advocates two models being created. In the first model, the dispensed medication is sent back to the spoke. In the second model, the completed
medication can be sent out directly to the patient.
The latter is a new concept which could open up new opportunities in how services are delivered. Pharmacies could effectively outsource the entire dispensing and
delivery to housebound patients and care homes allowing pharmacies to take on new business without having to worry about logistics and geography.
The Integrated Care Systems (ICSs) provide an opportunity to break the silo mentality in the health and care sector, National Pharmacy Association (NPA) chair
Andrew Lane told MPs.
While giving evidence to the Health and Social Care Select Committee on 6 December about the effectiveness of ICSs, Lane also poured cold water on newspaper reports
that community pharmacists will be drafted in to break the NHS strike, as he reiterated the call for a "properly costed and funded environment."
"We've been in different silos historically and ICSs are an opportunity to pull all systems together for the benefit of patients," he told committee members.
Lane pointed to dementia-trained pharmacy delivery drivers and the Discharge Medicines Service as instances where the influence of community pharmacy already
stretches beyond primary care into hospitals and social care.
"We've seen pharmacists prescribe and get UTIs off doctors' desks, so we are starting to release capacity [in the system] and we're on that clinical journey.
We welcome that, but it has to be with the right level of funding," he added.
The Medicines and Healthcare products Regulatory Agency (MHRA) on Tuesday authorised a Covid-19 vaccine for infants as young as six months, opening the door
for vaccinating the country's youngest children once the UK's Joint Committee on Vaccination and Immunisation (JCVI) agrees.
The regulator authorised the vaccine - made by Pfizer and BioNTech - for children aged six months to four years old, after it was deemed safe and effective based on
an ongoing clinical trial involving 4,526 participants.
Whether the vaccine is eventually deployed in this age group depends on a recommendation from the JCVI, which advises UK health departments on which shots should be
used as part of the national vaccination programme.
The vaccine is tailored for use in this age group - it is a lower dose version than the one used in children aged five to 11 years. It is given as three injections
in the upper arm, with the first two doses given three weeks apart, followed by a third dose administered at least two months after the second dose.
Community pharmacy bodies have said that the current crippling financial pressures and severe staff shortages will limit the sector from fully supporting the
new health secretary's ambition to improve patient care in England.
Thérèse Coffey announced her plans on Thursday (September 22) which would be looking to reduce the country's reliance on general practice by expanding the range of
services available from community pharmacies and allowing pharmacists more "prescribing powers".
"Pharmacists will be able to manage and supply more medicines, without a prescription from a GP. We will look to go further on enabling pharmacists with more
prescribing powers and making more simple diagnostic tests available in community pharmacy," she said in her foreword to Our Plan for Patients.
However, the National Pharmacy Association has lamented that the plan stops short of promising any fresh funding for community pharmacies to deliver patient care
and develop clinical services.
NPA vice-chair, Nick Kaye, said: "The life is being choked out of independent pharmacy businesses by the continuation of a fundamentally under-resourced contract
in England.
The large majority of adults in the England knew that flu jabs are available in many pharmacies, just over half were aware of the GP Community Pharmacist
Consultation Service or the New Medicine Service, according to a new survey by the National Pharmacy Association (NPA).
The new survey revealed the need to raise the public awareness of key NHS services such as the New Medicine Service.
According to the survey, 56 per cent of those asked believed that pharmacies in England offer NHS consultations for people newly prescribed a medicine for a
long-term condition.
While 48 per cent believed that many pharmacies in England offer blood pressure monitoring (NHS or private). 51 per cent believed it to be true that GPs can
formally refer patients for same-day clinical advice from their local pharmacist about minor ailments.
The Royal Pharmaceutical Society (RPS) Scotland the BMA's Scottish GP Committee has called for improvements to the pharmacotherapy service.
The joint statement released by the organisations on Friday (13 January), has recognised that much progress has been made but states that further improvements are
needed to fully maximise the benefits of the service.
It highlighted the need for better use of skill mix, including more clearly defining roles and responsibilities; improved IT enablers to reduce administrative burden;
and further developing a tandem model of working comprising hubs with in-practice activity
The two organisations state that inadequate funding and workforce shortages are a real threat to the pharmacotherapy service.
They have urge Scottish Government to reconsider its recent decision to reduce funding for training pharmacy technicians.
Clare Morrison, RPS Director for Scotland, said: "In the statement, we stress that the use of pharmacists' clinical skills must be maximised.
Doctors are highly driven professionals seeking exceptional care and service for their clients. Some doctors may have private practices, while others serve
in different capacities in various healthcare institutions. Doctors are among the busiest professionals in the field and may also experience burnout if they're not
careful.
Fortunately, there's an alternative to such a scenario, and more and more healthcare professionals are looking into it. Locum tenens jobs are on the rise as doctors,
and other health workers seek to take advantage of various benefits that can lead to a better career. While doctors hold down their private practice, they also work
with other institutions and colleagues to provide expertise to patients in other locations. This can be rewarding as the doctors can improve their craft tremendously.
Here are some reasons to consider if you wish to explore locum tenens posts.
Better control and schedule flexibility
While career stability is quite important for most doctors, it can be intense for some and lead to burnout. When taking a locum tenens position, a doctor will have
the opportunity to explore other horizons that present themselves. They can see other patients and be exposed to scenarios that may not be present in their practice.
Locum posts also allow you to set your schedule and be flexible with your working hours as necessary. It can lead to better performance and job satisfaction, too.
Opportunity for better income
Accepting a locum position may entail getting extra shifts at another hospital or clinic. It may also mean getting some time with patients during your off days. You
can receive a significant bump to your income as you get to earn more aside from your regular salary. If you're looking to pay off student loans, build a college
fund for your kids, or set up an account to buy a house, working with locum posts may be the key.
Sun Pharma has announced that it will acquire all outstanding shares of Concert Pharmaceuticals through a tender offer for an upfront payment of $8.00 per
share of common stock in cash, or $576 million in equity value.
The upfront payment of $8.00 per share of common stock in cash represents a premium of approximately 33% to Concert's 30-day volume weighted average price as of
January 18, 2023, the last trading day prior to today's announcement.
Concert is a late-stage biotechnology company pioneering the use of deuterium in medicinal chemistry. Concert has an extensive patent portfolio, including its lead
product candidate deuruxolitinib - an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease - which
is in late-stage development.
It has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3
clinical program and two open label, long-term extension studies are ongoing in North America and Europe. Sun Pharma's immediate focus would be to follow Concert's
plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2023.
Professional translators recreate texts, not simply matching word-for-word, but understanding the underlying meaning, purpose, and interpretation of the original
language, and reproduce it using appropriate terminology and structure to ensure there is no potential for misunderstanding.
An experienced technical translator addresses conventions to ensure the meaning of the information is preserved, using medical expertise and quality review processes
to adapt documentation to meet the needs of patients, medical practitioners, and peers.
Attention to detail is fundamental to medical translations and a non-technical translation is an unacceptably high risk for any organisation involved in publishing
or circulating medical information of any kind.
WHAT IS MEDICAL TRANSLATION?
Medical translation is a technical process where capable translators reproduce content or documentation used anywhere in the medical industry, including psychiatry,
systematic reviews, tuition and training, patient communications for pharmaceutical translation services.
Important clinical trial translations can include labelling, prescriptions, medical devices and patient records, with millions of medicines and treatments used
globally and written in multiple languages.
Qualified medical translators must have exceptional linguistic skills but also a thorough understanding of medical sciences in all the native languages concerned.
However, the complexity of translating one label or one document into several languages can mean that organisations may assume a simple translation is sufficient -
when it is anything but!
The health secretary, Steve Barclay was asked over the delay of 'Pharmacy First' model in England that was proposed by the Pharmaceutical Services Negotiating
Committee (PSNC) last year, at the Health Committee evidence session held on Tuesday (31 January).
Taiwo Owatemi MP (Chair of the Pharmacy APPG) asked whether he was adhering to his statutory responsibility to ensure continued access to medicines and cited the
CCA's closures in areas of deprivation research.
Barclay replied that the government is 'investing more'. He said, "We put an extra 100 million on top of the 2.6 billion a year we commit to community pharmacy to
expand the range of clinical services. We've got over 2 million patients that have been referred to community pharmacy from NHS."
He further added: "One of the issues I'm very keen on is to explore what more we can do in pharmacy not least given the pressures on GP and the opportunity to look
at what it is currently people go to GPS for where potentially the risk to do more at the pharmacy and we're already doing that."
Dry eye syndrome is incredibly common and prevalence is increasing globally. Studies show that prevalence rates vary from five to 50 per cent but can be as
high as 75 per cent in people over the age of 40, in people who wear contact lenses and those who work with computers. It is more common in women than in men,
particularly during and after the menopause.
According to a new real-world research commissioned by world experts in eye-care, Rohto, more than eight in ten women (83 per cent) indicate that they suffer from
the condition, but only once they have had the symptoms of dry eye syndrome described to them.
Without detailed explanation, 56 per cent of people say they have never even heard of dry eye syndrome, showing just how under diagnosed it may be.
Causes of dry eye
Dry eyes are a clinical cause of eye irritation, fatigue, and discomfort, often causing feelings of itchiness, grittiness, and excess watering. If left untreated,
dry eyes can even lead to long-term damage and sight problems.
Dry eyes may occur if enough tears aren't produced if poor-quality tears are generated or if the tears evaporate from the surface of the eye too quickly. This leads
to poor lubrication of the tear film. In a normal eye, the tear film4- the multilayer moist protective film - covers the cornea and lubricates the eye.
However, if the lubricative process is faulty dry spots appear on the surface of the eye and this causes irritation and discomfort. The tear film has several layers:
fatty oils, aqueous fluid, and mucus. This combination normally keeps the surface of your eyes lubricated, smooth and clear. But problems with any of these layers
can cause dry eyes.